Возможности коррекции проявлений метаболического синдрома у женщин в постменопаузе, не получающих заместительную гормональную терапию
Диссертация
С возникновением менопаузы у женщин повышается риск развития многих патологических состояний: атрофических изменений урогени-тального тракта, остеопороза, болезни Альцгеймера, онкологических заболеваний и т. д. Особое место занимают сердечно-сосудистые заболевания (ССЗ), как основная причина смерти людей этой возрастной группы. Это связано с тем, что на фоне дефицита эстрогенов в постменопаузе… Читать ещё >
Содержание
- Список сокращений
- Глава 1. Обзор литературы
- 1. 1. Ожирение в менопаузе — миф ил и факт?
- 1. 2. Современные представления о менопаузальном метаболическом синдроме
- 1. 2. 1. Абдоминальное ожирение — ключевое звено менопаузального метаболического синдрома?
- 1. 2. 2. Постменопауза и инсулинорезистентность
- 1. 2. 3. Влияние менопаузы на артериальное давление
- 1. 2. 4. Дислипопротеинемия в постменопаузальном периоде
- 1. 2. 5. Нарушение углеводного обмена
- 1. 2. 6. Маркеры иммунного воспаления и менопаузальный метаболический синдром
- 1. 2. 7. Перспективы профилактики сердечно-сосудистых осложнений при менопаузальном метаболическом синдроме
- 1. 2. 7. 1. Модификация образа жизни
- 1. 2. 7. 2. Заместительная гормональная терапия в пери- и постменопаузе
- 1. 2. 8. Гиполипидемическая терапия
- 1. 2. 9. Антигипертензивная терапия
- 1. 2. 10. Возможности медикаментозной терапии ожирения
- 1. 2. 10. 1. Лекарственные препараты, применяемые в настоящее время для лечения ожирения
- 1. 2. 10. 1. 1 Симпатомиметики
- 1. 2. 10. 1. 2 Сибутрамин
- 1. 2. 10. 1. 3 Орлистат
Список литературы
- Аничков ДА., Шостак Н. А. Эффективность моксонидина у женщин с артериальной гипертензией в рамках метаболического синдрома при исходно высокой частоте сердечных сокращений. // Кардиология. 2002. — 11. -40−3.
- Григорян О.Р., Чернова Т. О., Анциферов М. Б. Коррекция инсулинорези-стентности у женщин в постменопаузе. // Проблемы репродукции.
- Кобалава Ж.Д., Котовская Ю. В. Артериальная гипертония 2000: ключевые аспекты диагностики, дифференциальной диагностики, профилактики, клиники и лечения. Москва 2001 г. С 49
- Подзолков ВИ, Брагина АЕ, Маколкин ВИ. Патогенетическая роль моксонидина при лечении артериальной гипертензии у женщин в перименопау-зе. // Кардиология. 2002. — 11.- 32−5.
- Профилактика, диагностика и лечение первичной артериальной гипертонии в Российской Федерации. // Клин, фармакол. тер. 2000. — 2. — 5−30.
- Репина М.А. Менопаузальный метаболический синдром и ожирение Жур-налъ акушерства и женских болезней. // том LIE. выпуск 3. — 2003. — с. 7584
- Сметник ВП, Шестакова И. Г. Менопауза и сердечно-сосудистая система. Тер. арх. //1999. 10. — 61−5.
- Старкова Н.Т., Попков С. А., Верткин М. А. Опыт применения препарата «ДИВИНА» у больных климактерическим синдромом на фоне сахарного диабета 2 типа // Методологические и социальные проблемы медицины и биологии: Сб.науч.тр.-М., 1995 Вып.2 — С.128−129.
- Шестакова И.Г. Влияние комбинированной ЗГТ 17Ь-эстрадиолом с дидро-гестероном на углеводный обмен, массу тела и распределение жировой ткани у женщин в постменопаузе // Климактерий и постменопауза. 1999.-№ 4.-13−15.
- Abramson JL, Weintraub WS, Vaccarino V. Association between pulse pressure and C-reactive protein among apparently healthy US adults. // Hypertension. 2002. -39.-197−202.
- Adnan G, Gumurdulu Y, Karakose H, et al. Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity abstract. // Int J Obes. 2001. — 25 Suppl. 2. — S111.
- American College of Obstetricians and Gynecologists. Available at: http:// www.acog.org. Accessed April 7, 2004.
- Aronson D, Rayfield EJ. How hyperglycemia promotes atherosclerosis: molecular mechanisms. // Cardiovasc Diabetol. -2002. -1.- 1.
- Barbagallo M, Dominguez LJ, Licata G, Resnick LM. Effects of aging on serum ionized and cytosolic free calcium: relation to hypertension and diabetes. // Hypertension. 1999. — 34. — 902−6.
- Barnabei VM, Grady D, Stovall DW, et al. Menopausal symptoms in older women and the effects of treatment with hormone therapy. Obstet Gynecol. -2002. -100. 1209−1218.
- Barrett-Connor E, Slone S, Greendale G, et al. The Postmenopausal Estro-gen/Progestin Interventions Study (PEPI): primary outcomes in adherent women. II Maturitas. 1997. — 27. — 261 -274.
- Barrett-Connor EL, Cohn B, Wingard D et al. Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? JAMA //1991. 265. — 627−31
- Bjorkelund C, Lissner L, Andersson S, Lapidus L, Bengtsson C. Reproductive history in relation to relative weight and fat distribution. И Int J Obes Relat Me-tab Disord. 1996. — 20(3). — 213−9.
- Bolego C, Poli A, Paoletti R. Cardiovascular risk in diabetic women. Curr Atheroscler Rep // 2003. 5. — 79−81.
- Borisova AM, Tankova Ts, Kamenova P, et al. Cyproterone acetate improves beta-cell function in postmenopausal women with diabetes mellitus type 2. Article in Bulgarian. //Akush Ginekol (Sofiia). 2003. — 42(5). — p.p. 8−14.
- Brochu M, Starling RD, Tchernof A et al. Visceral adipose tissue is an independent correlate of glucose disposal in older obese postmenopausal women. // J Clin Endocrinol Metab. 2000. — 85. — 2378−84.
- Carr MC. The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab 2003- 88: 2404−11
- Carranza LS, Murillo UA, Martinez TN, Santos GJ. // Int J Fertil. 1998. — 43. -p.p. 306−11
- Cefalu W. The use of hormone replacement therapy in postmenopausal women with type 2 diabetes. // J Womens Health Gend Based Med 10:241 255, 2001.
- Chae CU, Lee RT, Rifal N, Ridker PM. Blood pressure and inflammation in apparently healthy men. // Hypertension. 2001. — 38. — 39903
- Clarke SC, Kelleher J, Lloyd-Jones H, Slack M, Schofiel PM. A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: the Papworth HRT atherosclerosis study. (PHASE). // Br J Obstet Gynaecol. 2002. — 109. -1056−1062.
- Colditz GA, Willett WC, Rotnitzy A, Manson JE. Ann Intern Med 1995- 122(7):481−486
- Collaborative Group on Hormonal Factors in Breast Cancer. Lancet. 1997- 350: 1047
- Das UN. Metabolic syndrome X: an inflammatory condition? // Curr Hypertens Rep.-2004.-6.-66−73.
- Davison MH, Hauptman J, DiGirolamo M et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA. 1999- 281:235−42.
- Didangelos T. P.- Thanopoulou A. K.- Bousboulas S. H., et al. The ORLIstat and CArdiovascular Risk Profile in Patients With Metabolic Syndrome and Type 2 DIAbetes (OR LI CARD I A) Study. // Curr Med Res Opin. 2004. — 20(9). — 1393−1401.
- Douchi T, Yamamoto S, Nakamura S et al. // Maturitas. 1998. — 29. — p.p. 247−52.
- Drent ML, Larsson I, Williamolsson T, et al. Orlistat (RO 18−0647), a lipase inhibitor, in the treatment of human obesity: a multiple dose study. // Int J Obes. -1995.-19.-221−6.
- Effects of estrogen or estrogen/progestin regimens on heart diseases risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995- 273: 199−208.
- Engeli S, Feldpausch M, Gorzelniak К et al. Association between adiponectin and mediators of inflammation in obese women. // Diabetes. 2003. — 52. -942−7.
- Esposito K, Pontillo A, Di Palo С et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. // JAMA. 2003. — 289. — 1799−804.
- European guidelines on cardiovascular diseases prevention in clinical practice. // Eur J Cardiovasc Prev Rehabil. 2003. — 10. — S1−10.
- European Multicentre Orlistat Study Group. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet. 1998- 352:167−72.
- Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). // JAMA 2001. -285. 2486−97.
- Faria AN, Ribeiro Filho FF, Gouveia Ferreira SR, Zanella MT. Impact of visceral fat on blood pressure and insulin Sensitivity in hypertensive obese women. // Obes Res. 2002. — 10. -1203−6.
- Feldstein CA, Akopian M, Renauld A et al. Insulin resistance and hypertension in postmenopausal women. IIJ Hum Hypertens. -2002. -16 (Suppl. 1): S145−50.
- Ferrara A, Karter AJ, Ackerson LM, et al. Hormone replacement therapy is associated with better glycemic control in women with type 2 diabetes, the Northern California Kaiser Permanente Diabetes Registry. // Diabetes Care 24:1144−1150, 2001.
- Festa A, D’Agostino R, Howard G et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). // Circulation. 2000. — 102. — 42−7.
- Finer N, James WPT, Kopelman PG, et al. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. // Int J Obes. 2000. — 24. — 306−13.
- Fisman EZ, Tenenbaum A, Pines A. Systemic hypertension in postmenopausal women: a clinical approach. // Curr Hypertens Rep. 2002. — 4. — 464−70.
- Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA 2002- 287: 356−9.
- Ford ES. The metabolic syndrome and mortality from cardiovascular disease and all causes: findings from the National Health and Nutrition Examination Survey II Mortality Study. Atherosclerosis 2004−173:307−12
- Friday K, Dong C, Fontenot R: Conjugated equine estrogen improves glycemic control and blood lipoproteins in postmenopausal women with type 2 diabetes. // J Clin Endocrinol Metab 86:48−52, 2001
- Frochlich M, Imhof A, Berg G et al. Association between C-reactive protein and features of the metabolic syndrome: a population-based study. // Diabetes Care. 2000. -23.- 1835−9.
- Gordon S, Walsh BW, Ciaccia AV, Siddhanti S, Rosen AS, Plouffe L. Transition from estrogen-progestin to raloxifene in postmenopausal women: effect on vasomotor symptoms. II Obstet Gynecol. 2004. — 103.- 267−273.
- Grady D, Herrington D, Bittner V, et al, for the HERS Research Group. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). // JAMA. 2002. -288. — 49−57.
- Grodstein F, Lifford K, Resnick NM, Curhan GC. Postmenopausal hormone therapy and risk of developing urinary incontinence. Nurses' Health Study // Obstet Gynecol. 2004. -103. -254−260.
- Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Nurses' Health Study // Ann Intern Med.-2000.-133. -933−941.
- Grodstein F, Stampfer MJ, Manson JE, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. Nurses' Health Study // N Engl J Med. 1996. — 335. — 453−461.
- Guerciolini R. Mode of action of orlistat. // Int J Obes. 1997. — 21 Suppl. 3. -12−23.
- Haas JS, Kaplan CP, Gerstenberger EP, Kerlikowske K. Changes in the Use of Postmenopausal Hormone Therapy after the Publication of Clinical Trial Results//Ann Intern Med. -2004. -140. 184−188.
- Haenni A, Lithell H. Moxonidine improves insulin sensitivity in insulin-resistant hypertensives. // J Hypertens. 1999. — 17 (Suppl. 3). — S29−35.
- Han TS, Sattar N, Williams К et al. Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. // Diabetes Care. 25. — 2016−21
- Hauptman J, Lucas C, Boldrin MN, et al. Orlistat in the long-term treatment of obesity in primary care settings. //Arch Fam Med. 2000. — 9. -: 160−7.
- Hays J, Ockene JK, Brunner RL, et al, for the Women’s Health Initiative Investigators. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med 2003−348:1839−1854.
- Hernandez-Ono A, Monter-Carreola G, Zamora-Gonzalez J et al. Association of visceral fat with coronary risk factors in population-based sample of postmenopausal women. // Int J obes Relat Metab Disord. -.2001. 26. — 33−9.
- Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. Estrogen Replacement and Atherosclerosis (ERA) trial. // N Engl J Med. 2000. — 343. -522−529.
- Herrington DM, Vittinghoff E, Lin F, et al, for the HERS Study Group. Statin therapy, cardiovascular events, and total mortality in the Heart and Estro-gen/Progestin Replacement Study (HERS). Circulation. 2002. — 105. — 29 622 967.
- Hill JO, Hauptman J, Anderson JW, et al. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: one 1-y study. Am J Clin Nutr. -1999.-69.- 1108−16.
- Howard BV, Cowan LD, Go О et al. Adverse effects of diabetes on multiple cardiovascular disease risk factors in women. // Diabetes Care. — 1998. — 21.1258−65.
- Hsia J, Simon JA, Lin F, et al. Peripheral arterial disease in randomized trial of estrogen with progestin in women with coronary heart disease: the Heart and Estrogen/Progestin Replacement Study. // Circulation. 2000. -102. — 22 282 232.
- Hu FB, Manson JE, Stampfer MJ et al. Diet, lifestyle, and the risk of type 2 dia-. betes mellitus in women. // N Engl J Med. 2001. — 345. — 790−7.
- Hulley S, Furberg C, Barrett-Connor E, et al, for the HERS Research Group. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). // JAMA. 2002. — 288. — 58−66.
- Hvizdos KM, Markham A. Orlistat: a review of its use in the management of obesity. // Drugs. 1999. — 58. — 743−60.
- Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. // Diabetes Care 2001−24:683−9
- Jneidi M- Kelley DE. Orlistat in the treatment of Type 2 diabetes mellitus. // Expert Opinion on Pharmacotherapy. 2002. 3. — 5. — p.p. 599 — 605.
- Kanaya AM, Herrington D, Vittinghoff E, et al. Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/progestin Replacement Study. //Ann Intern Med. -2003. 138:1−9.
- Kern PA, Di Georgio GB, Lu T et al. Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-a expression. // Diabetes. 2003. — 52: — 1779−85.
- Kim HS, Abbasi F, Lamendola С et al. Effect of insulin resistance on postprandial elevations of remnant lipoprotein concentrations in postmenopausal women. //Am J Clin Nutr. -2001. -74. 592−5.
- Kissebah AH, Freedman DS, Periris AN. Health risks of obesity. Med Clin North Am. 1989- 111−138
- Klein BE, Klein R, Lee KE. Components of the metabolic syndrome and risk of cardiovascular disease and diabetes in Beaver Dam. // Diabetes Care. 2002. -25. — 1790−4.
- Kotchen JM, Kotchen ТА. Impact of female hormones on blood pressure: review of potential mechanisms and clinical studies. Curr Hypertens Rep 2003- 5: 505−12.
- Krempf M, Louvet J-P, Allanic H, et al. Orlistat associated with a hypocaloric diet in obese patients promotes and maintains weight loss during an 18-month period abstract. // Diabetes. 2001. — 50. — Suppl. 2.-21.
- La Rosa JC. Evidence-based management of dyslipidemias in women. // Curr Atheroscler Rep. 2003. — 5. — 379−85.
- Lew EA, Garfinkel L. Variations in mortality by weight among 750 000 men and women. J Chronic Dis. 1979- 32: 563 576.
- Ley С J, Lees B, Stevenson JC. 1992 Sex- and menopause-associated changes in body fat distribution. //Am J Clin Nutr. 5. — 950−954.
- Lin Y, Rajala MW, Berger JP et al. Hyperglycemia-induced production of acute phase reactants in adipose tissue. J Biol Chem 2001- 276: 42 077−83.
- Lindgarde F. The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multi-morbidity Study. J Intern Med. -2000.-248.-245−54.
- Lokkegaard E, Pedersen AT, Heitmann BL, Jovanovic Z, et al. Relation between hormone replacement therapy and ischaemic heart disease in women: prospective observational study. // BMJ. 2003. — 326. — 426- 32.
- Lorenzo C, Okoloise M, Williams K, Stern MP, Haffner SM- San Antonio Heart Study. 2003 The metabolic syndrome as predictor of type 2 diabetes: the San Antonio heart study. // Diabetes Care. 26. — 3153−3159.
- Lovergrove JA, Silva KDRR, Wright JW, Williams CM. Adiposity, insulin and lipid metabolism in post-menopausal women. // Int J Obes Relat Metab Disord. -2002.-26.-475−86.
- Manning PJ, Sutherland WH, Allum AR, et al. HRT does not improve urinary albumin excretion in postmenopausal diabetic women. // Diabetes Res Clin Pract. 2003. — Apr. — 60(1), -: p.p. 33−9.
- Manson JE, Hsia J, Johnson КС, et al, for the Women’s Health Initiativelnves-tigators. Estrogen plus progestin and the risk of coronary heart disease. Women’s Health Initiative (WHI). // N Engl J Med. -2003. 349. — 523−534.
- Milewicz A, Bidziska B, Sidorowicz A. Perimenopausal obesity. // Gynecol Endocrinol. 1996. -10(4). — 285−91.
- Milewicz A, Tworowska U, Demissie M. Menopausal obesity myth or fact? // Climacteric. — 2001. — 4. — 273 — 283.
- Millar WJ, Stephens T. The prevalence of overweight and obesity in Britain, Canada, and United States. //Am J Public Health. 1987. — 77(1). — 38−41.
- Miller AM, Wilbur J, Chandler PJ, Sorokin O. Cardiovascular disease risk factors and menopausal status in midlife women from the former Soviet Union. // Women Health. -2003. -38. -19−36.
- Mostaghel E, Waters D. Women do benefit from lipid lowering: latest clinical trial data. Cardiol Rev 2003- 11: 4−12.
- Nickenig G, Baumer AT, Grohe С et al. Estrogen modulates AT1 receptor gene expression in vitro and in vivo. // Circulation. 1998. — 97.: 2197−201
- Nilsson PM, Lind L, Pollare T, et al. Differences in insulin sensitivity and risk marker due to gender and age in hypertensives. // J Hum Hypertens. 2000. -14.-51−6.
- Ninomiya JK, L’ltalien G, Criqui MH, et al. Association of the metabolic syndrome with history of myocardial infarction and stroke in the third national health and nutrition examination survey. // Circulation. 2004/ -109. — 42−6/
- Obesity in Scotland. Scottish Intercollegiate Guidelines Network, November 1996 with modifications for more robust BMR estimates in the elderly age group.
- Palin S, Kumar S, Sturdee D, Barnett A. Hormone replacement therapy for postmenopausal women with diabetes. // Diabetes Obes Metab 3:187−193, 2001
- Pasquali R, Casimirri F, Labate A et al. Body weight, fat distribution and the menopausal status in women. // Int J Obesity. 1994. -18.-14−21.
- Pfeilschifter J, Koditz R, Pfohl M, Schatz H. Changes in proinflammatory cytokine activity after menopause. // Endocr Rev. 2002. — 23. — 90−119.
- Poehlman ET, Toth MJ, Ades PA, Rosen CJ. // Eur J Clin Invest. 1997. — 27. -p.p. 322−6.
- Rendell M, Hulthen UL, Tornquist С et al. Relationship between abdominal fat compartments and glucose and lipid metabolism in early postmenopausal women. //J Clin Endocrinol Metab. 2001. — 86. — 744−9.
- Ridker PM, Rifai N, Rose L et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. // N Engl J Med. 2002. — 347. — 1557−65.
- Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. // Circulation. -2001.-103.- 1813−8.
- Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. // JAMA. 2002. — 288. — 321−33.
- Rosa JC. Evidence-based management of dyslipidemias in women. // Curr Atheroscler Rep. 2003. — 5. — 379−85.
- Rosental T, Oparil S. Hypertension in women. // J Hum Hypertens. 2000. -14.-691−704.
- Rossner S, Sjostrom L, Noack R, et al. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. // J Obes Res. 2000. — 8. — 49−61.
- Salpeter SR, Walsh JME, Greyber E, Ormiston TM, Salpeter EE. Mortality associated with hormone replacement therapy in younger and older women: a meta-analysis. // J Gen Intern Med. 2004. — 19. — 791−804.
- Scarabin PY, Oger E, Plu-Bureau G, for the Estrogen and THrombo-Embolism Risk Study Group (THER). Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. // Lancet. -2003. 362. — 428−432.
- Schillaci G, Verdecchia P, Borgioni С et al. Early cardiac changes after menopause. // Hypertension. 1998. — 32. — 764−9.
- Sciacqua A, Candigliota М, Ceravolo R et al. Weight loss in combination with physical activity improves endothelial dysfunction in human obesity. // Diabetes Care. 2003. — 26. — 1673−8.
- Scott AR, Dhindsa P, Forsyth J, Mansell P- Kliofem Study Collaborative Group. Effect of hormone replacement therapy on cardiovascular risk factors in postmenopausal women with diabetes. // Diabetes Obes Metab. 2004. — 6(1). -p.p. 16−22.
- Sherwood A, Thurston R, Steffen P et al. Blunted nighttime blood pressure dipping in postmenopausal women. //Am J Hypertens. 2001. — 14. — 749−54.
- Simkin-Silverman LR, Wing et al. Maintenance of cerdiovascular risk factors changes among middle-aged women in a lifestyle intervention trial Women’s Health. 1998:4: 255−71.
- Simon JA, Hsia J, Cauley JA, et al. Postmenopausal hormone therapy and risk of stroke: the Heart and Estrogen-progestin Replacement Study (HERS). // Circulation. 2001. — 103. — 638−642.
- Sjostrom L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. // Lancet. 1998. — 18. — 352. — 167−72.
- Soules MR, Sherman S, Parrott E, Rebar R, Santoro N, Utian W, Woods N. Executive summary: Stages of Reproductive Aging Workshop (STRAW). // Climacteric. 2001. — 4(4). — 267−72.
- Sowers JR. Diabetes mellitus and cardiovascular disease in women. // Arch Intern Med. 1998. — 158. — 617−21.
- Spencer CP, Godsland IF, Stevenson JC. Is there a menopausal metabolic syndrome? // Gynecol Endocrinol. 1997. — 11. — 341−55.
- Staessen J, Bulpit CJ, Fagard R et al. The influence of menopause on blood pressure. // J Hum Hypertens. 1989. — 3. — 427−33.
- Staessen J, Ginocchio G, Thijs L, Fagard R. Conventional and ambulatory blood pressure and menopause in a prospective population study. // J Hum Hypertens. 1997. — 11. — 507−14.146.147.148.149.150 151 152 153 154 162 275 157 257 748 480
- Stephenson J. FDA orders estrogen safety warnings: agency offers guidance for HRT use. // JAMA. 2003. — 289. — 537−538.
- Svendsen OL, Hassager C, Christiansen C. 1995 Age- and menopause associated variations in body composition and fat distribution in healthy women as measured by dual-energy x-ray absorptiometry. // Metabolism. 44. — 369 -373.
- The North American Menopause Society. Menopause Practice: A Clinician’s Guide, http: // www.menopause.org/ edumaterials/ cliniciansquide/ clinicians-quide.htm 10.2004. 266 p.
- The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. // NIH Publication № 35 233 May 2003.
- The Writing Group for the ISCD Position Development Conference 2004/ Executive Summary: International Society for Clinical Dencitometry Position Development Conference, Cincinnati Ohio. // J. Clin. Dencitom.7. p.p. — 7 — 12.
- Toplak H. Efficacy and safety of orlistat plus a reduced-calorie diet in obese non-diabetic patients: a 1-year Austrian multicentre study abstract. // Int J Obes. 200. — 25. — Suppl. — 2. — S112
- Toth MJ, Sites CK, Eltabbakh GH, Poehlman ET. Effect of menopausal status on insulin-stimulated glucose disposal: comparison of middle-aged premenopausal and early postmenopausal women. // Diabetes Care. 2000. — 23. -801−6.
- Toth MJ, Tchernof A, Sites CK, Poehlman ET. 2000 Effect of menopausal status on body composition and abdominal fat distribution. // Int J Obes Relat Metab Disord. 24. — 226−231.
- Trevisan M, Liu J, Bahsas FB, Menotti A. Syndrome X and mortality: a population-based study. Am J Epidemiol 1998−148:958−66.
- Troisi R, Cowie C, Harris M. Hormone replacement therapy and glucose metabolism. // Obstet Gynecol 96:665−670, 2000.
- Tsuda K, Kinoshita Y, Kimura К et al. Electron paramagnetic resonance investigation on modulatory effect of 17b-estradiol on membrane fluidity of erythrocytes in postmenopausal women. // Arteioscler Thromb Vase Biol. 2001. -21. — 1306−12
- Utian WH. Semantics, menopause-related terminology, and the STRAW reproductive aging staging system. // Menopause. 2001. — 8(6). — 398−401.
- Van Gaal LF, Broom Jl, Enzi G, et al. Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. // Eur J Clin Pharmacol. -1998.-54.-125−32.
- Van Pelt RE, Evans EM, Schechtman KB et al. Waist circumference vs body mass index for prediction of disease risk in postmenopausal women. // Int J Obes Relat Metab Disord. 2001. — 25. -1183−8.
- Vilecco AS, de Aloyso D, Radi D et al. Plasma catecholamines in pre- and postmenopausal women with mild to moderate essential hypertension. // J Hum Hypertens. -1997. -11.- 152−62.
- Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz Rl. A clinical trial of estrogen-replacement therapy after ischemic stroke. Women’s Estrogen for Stroke Trial (WEST) // N Engl J Med. -2001. -345. -1243−49.
- Vongpatanasin W, Tuncel M, Mansour Y et al. Transdermal estrogen replacement therapy decreases sympathetic activity in postmenopausal women. // Circulation. -2001. 103. — 2903−8.
- Walton C, Godsland IF, Proudler AJ et al. The effects of the menopause on insulin sensitivity, secretion and elimination in non-obese, healthy women. // Eur J Clin Invest. 1993. — 23. — 466−73.
- Wassertheil-Smoller S, Anderson G, Psaty BM et al. Hypertension and its treatment in postmenopausal women: baseline data from Women’s Health Initiative. // Hypertension. 2000. — 36. — 780−9.
- Wassertheil-Smoller S, Hendrix SL, Limacher M, et al, for the WHI Investigators. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women’s Health Initiative: a randomized trial. // JAMA. 2003. — 289. -2673−2684.
- Wilson PW, Kannell WB, Silbershatz H, D’Agostino RB. Clustering of metabolic factors and coronary heart disease. //Arch Intern Med. 1999. — 159. — 1104— 9.
- Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. // JAMA. -2002−288:321−333.
- Wu SI, Chou P, Tsai ST. 2001 The impact of years since menopause on the development of impaired glucose tolerance. // J Clin Epidemiol. 54. — 117 120.